September 12, 2022
Selexis and NexImmune Sign Service Agreement to Advance Multiple Immunotherapies Targeting Rare Cancers and Autoimmune Disorders
Agreement supports the development of molecules targeting acute myeloid leukemia, multiple myeloma, human papilloma virus…
